Gilead Sciences (GILD)
103.63
+2.23 (2.20%)
NASDAQ · Last Trade: Apr 12th, 11:00 AM EDT
Detailed Quote
Previous Close | 101.40 |
---|---|
Open | 102.18 |
Bid | 103.20 |
Ask | 105.00 |
Day's Range | 100.76 - 104.79 |
52 Week Range | 62.07 - 119.96 |
Volume | 8,683,686 |
Market Cap | 129.93B |
PE Ratio (TTM) | 280.08 |
EPS (TTM) | 0.4 |
Dividend & Yield | 3.080 (2.97%) |
1 Month Average Volume | 10,637,002 |
Chart
About Gilead Sciences (GILD)
Gilead Sciences is a biopharmaceutical company that focuses on the research, development, and commercialization of innovative therapeutics to address significant unmet medical needs, particularly in the fields of antiviral therapies, oncology, and inflammation. The company is well-known for its advancements in treatments for diseases such as HIV, hepatitis C, and influenza, while also expanding its portfolio to include oncology products and therapies for other serious conditions. Gilead is committed to improving patient outcomes through its cutting-edge science and collaborative efforts, working to develop medicines that have both transformative efficacy and address critical health challenges on a global scale. Read More
News & Press Releases
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.
Via Benzinga · April 11, 2025
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s first quarter 2025 financial results and provide a business update.
By Gilead Sciences, Inc. · Via Business Wire · April 10, 2025
Here's why the 90-day tariffs delay doesn't help pharmaceutical companies.
Via Investor's Business Daily · April 10, 2025
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.
Via Benzinga · April 9, 2025
The US market session of Wednesday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today.
Via Chartmill · April 9, 2025
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports.
Via Investor's Business Daily · April 9, 2025
Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.
Via Benzinga · April 4, 2025
Via Benzinga · April 3, 2025
Intel's new CEO, Lip-Bu Tan, offered his strategy for turning around the troubled chipmaker in a speech late Monday. But Intel stock fell.
Via Investor's Business Daily · April 1, 2025
JPMorgan's upgrade on Gilead sparks bullish sentiment for the healthcare sector—here's why stocks like Pfizer and Hims & Hers are promising opportunities.
Via MarketBeat · April 1, 2025
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 11.1%. This drop was worse than the S&P 500’s 4% decline.
Via StockStory · March 31, 2025
Via Benzinga · March 27, 2025
Via Benzinga · March 27, 2025
The FDA is due to make an approval decision in mid-September for a key product from the top pharma company.
Via Investor's Business Daily · March 27, 2025
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.
Via Benzinga · March 21, 2025
Despite the pullback, we have found numerous opportunities which we discuss in this video using technical analysis.
Via Talk Markets · March 23, 2025
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers.
Via StockStory · March 21, 2025
Let's have a look at the S&P500 gap up and gap down stocks in today's session.
Via Chartmill · March 20, 2025
The company has a portfolio of HIV prevention treatments such as Biktarvy and Descovy.
Via Stocktwits · March 20, 2025
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.
Via Chartmill · March 19, 2025
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session.
Via Chartmill · March 19, 2025
Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session.
Via Chartmill · March 19, 2025